Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-17T07:59:33.477Z Has data issue: false hasContentIssue false
  • English
  • Français

Fibromyalgia: Key Clinical Domains, Comorbidities, Assessment, And Treatment

Published online by Cambridge University Press:  07 November 2014

Philip J. Mease
Get access Rights & Permissions [Opens in a new window]

Extract

In discussion of the best practices for patients with fibromyalgia (FM), it is key to Introduce commentary about what FM is as a clinical condition, how clinicians should assess for FM, and the pharmacologic approaches to management.

The first widely accepted criteria for the classification for FM were published in 1990 as the American College of Rheumatology criteria for FM. However, the condition has long been described in medical history. In the 1800s, a condition similar to FM was labeled “neurasthenia” and was further defined by researchers in the medical literature. During the early 1900s, symptoms associated with FM were labeled “fibrositis,” which was based on the mistaken idea that there were inflammatory changes in peripheral connective tissue. It was not until the mid-1970s when pioneering work by Smythe and Moldofsky defined central nervous system abnormalities, including significant sleep pathology, in patients with this condition that led to the increased recognition by researchers and clinicians that FM was a central pain phenomenon.

Following this critical development, use of the term “fibromyalgia” began and was codified in the 1990 criteria, intended for use in research settings to standardize classification of FM. The 1990 criteria classify the condition as involving chronic widespread pain for at least 3 months. Patients must also exhibit tenderness of at least 11 of 18 tender points.

Type
Research Article
Information
CNS Spectrums , Volume 14 , Issue S16: Fibromyalgia Facts: Foundations for Assessment, Care, and Treatment Strategies , August 2009 , pp. 6 - 9
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Wolfe, F, Smythe, HA, Yunus, MB, et al.The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160–172.CrossRefGoogle ScholarPubMed
2.Inanici, F, Yunus, MB. History of fibromyalgia: past to present. Curr Pain Headache Rep. 2004;8(5):369–378.CrossRefGoogle ScholarPubMed
3.Smythe, HA, Moldofsky, H. Two contributions to understanding of the “fibrositis” syndrome. Bull Rheum Dis. 1977–1978;28(1):928–931.Google ScholarPubMed
4.Mease, PJ, Clauw, DJ, Arnold, LM, et al.Fibromyalgia syndrome. J Rheumatol. 2005;32(11):2270–2277.Google ScholarPubMed
5.Wolfe, F, Clauw, DJ, Fitzcharles, MA, et al.Clinical Diagnostic and Severity Criteria for Fibromyalgia. Paper presented at: the 73rd Annual Scientific Meeting of the College of Rheumatology/Association of Rheumatology Health Professionals; October 18, 2009; Philadelphia, PA.Google Scholar
6.Aaron, LA, Burke, MM, Buchwald, D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221–227.CrossRefGoogle ScholarPubMed
7.Weir, PT, Harlan, GA, Nkoy, FL, et al.The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol. 2006;12(3):124–128.CrossRefGoogle ScholarPubMed
8.Lawrence, RC, Felson, DT, Helmick, CG, et al.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35.CrossRefGoogle ScholarPubMed
9.Wolfe, F, Ross, K, Anderson, J, Russell, IJ, Hebert, L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19–28.CrossRefGoogle ScholarPubMed
10.Hartz, A, Kirchdoerfer, E. Undetected fibrositis in primary care practice. J Fam Pract. 1987;25(4):365–369.Google ScholarPubMed
11.Neumann, L, Buskila, D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7(5):362–368.CrossRefGoogle ScholarPubMed
12.Eraso, RM, Bradford, NJ, Fontenot, CN, Espinoza, LR, Gedalia, A. Fibromyalgia syndrome in young children: onset at age 10 years and younger. Clin Exp Rheumatol. 2007;25(4):639–644.Google ScholarPubMed
13.Senna, ER, De Barros, AL, Silva, EO, et al.Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol. 2004;31(3):594–597.Google Scholar
14.Farooqi, A, Gibson, T. Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br J Rheumatol. 1998;37(5):491–495.CrossRefGoogle ScholarPubMed
15.Choy, EH, Arnold, LM, Clauw, DJ, et al.Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009;36(10):2330–2334.CrossRefGoogle ScholarPubMed
16.Mease, P, Arnold, LM, Choy, EH, et al.Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36(10):2318–2329.CrossRefGoogle ScholarPubMed
17.Mease, P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6–21.Google ScholarPubMed
18.Burckhardt, CS, Clark, SR, Bennett, RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18(5):728–733.Google ScholarPubMed
19.Arnold, LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther. 2006;8(4):212.CrossRefGoogle ScholarPubMed
20.Goldenberg, DL, Burckhardt, C, Crofford, L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388–2395.CrossRefGoogle ScholarPubMed
21.Clauw, DJ, Crofford, LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17(4):685–701.CrossRefGoogle ScholarPubMed
22.Arnold, LM, Goldenberg, DL, Stanford, SB, et al.Gabapentin in the treatment of fibromyalgia: a randomzed, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336–1344.CrossRefGoogle Scholar
23.Arnold, LM. Systemic therapies for chronic pain. In: Wallace, DJ, Clauw, DJ, eds. Fibromyalgia and Other Central Pain Syndromes. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.Google Scholar
24.Carette, S, McCain, GA, Bell, DA, Fam, AG. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum. 1986;29(5):655–659.CrossRefGoogle ScholarPubMed
25.Carette, S, Bell, MJ, Reynolds, WJ, et al.Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37(1):32–40.CrossRefGoogle ScholarPubMed
26.Ginsberg, F, Mancaux, A, Joos, E, Vanhove, P, Famaey, JP. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain. 1996;4(3):37–47.CrossRefGoogle Scholar
27.Hannonen, P, Malminiemi, K, Yli-Kerttula, U, Isomeri, R, Roponen, P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37(12):1279–1286.CrossRefGoogle ScholarPubMed
28.Heymann, RE, Helfenstein, M, Feldman, D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol. 2001;19(6):697–702.Google ScholarPubMed
29.Caruso, I, Sarzi Puttini, PC, Boccassini, L, et al.Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1987;15(3):154–159.CrossRefGoogle ScholarPubMed
30.Bennett, RM, Gatter, RA, Campbell, SM, Andrews, RP, Clark, SR, Scarola, JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988;31(12):1535–1542.CrossRefGoogle ScholarPubMed
31.Mease, PJ, Clauw, DJ, Gendreau, RM, et al.The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398–409.CrossRefGoogle ScholarPubMed
32.Clauw, DJ, Mease, P, Palmer, RH, Gendreau, RM, Wang, Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988–2004.CrossRefGoogle ScholarPubMed
33.Gendreau, RM, Thorn, MD, Gendreau, JF, et al.Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32(10):1975–1985.Google ScholarPubMed
34.Russell, IJ, Mease, PJ, Smith, TR, et al.Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–444.CrossRefGoogle ScholarPubMed
35.Arnold, LM, Rosen, A, Pritchett, YL, et al.A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5–15.CrossRefGoogle ScholarPubMed
36.Arnold, LM, Lu, Y, Crofford, LJ, et al.A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974–2984.CrossRefGoogle ScholarPubMed
37.Crofford, LJ, Rowbotham, MC, Mease, PJ, et al.Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264–1273.CrossRefGoogle ScholarPubMed
38.Bennett, RM, Schein, J, Kosinski, MR, Hewitt, DJ, Jordan, DM, Rosenthal, NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53(4):519–527.CrossRefGoogle ScholarPubMed
39.Bennett, RM, Kamin, M, Karim, R, Rosenthal, N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114(7):537–545.CrossRefGoogle Scholar
40.Kemple, KL, Smith, G, Wong-Ngan, J. Opioid therapy in fibromyalgia- A four year prospective evaluation of therapy selection, efficacy, and predictors of outcome. Arthritis Rheum. 2003;48:S88.Google Scholar
41.Goldenberg, DL, Felson, DT, Dinerman, H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29(11):1371–1377.CrossRefGoogle ScholarPubMed
42.Clark, S, Tindall, E, Bennett, RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. 1985;12(5):980–983.Google ScholarPubMed